Close Menu

AGBT

The Telomere-to-Telomere consortium has already generated a gapless assembly of the human X chromosome and aims to complete all chromosomes over the next two years or so.

Early-access users have used IDT's rhAmpSeq technology to create genetic marker maps for plants and to validate off target events in gene editing.

 

Five early customers are currently operating the Sequel II, which promises an eightfold increase in throughput, making reference genome sequencing feasible.

The company is working on nanopore technologies for sensing or sequencing applications, which it aims to commercialize through a partner.

At the AGBT conference, MGI Tech showcased its technologies, while a Sanger Institute researcher presented results from a comparison between BGI and Illumina data.

Researchers are turning to spatial technologies to study tumor heterogeneity and as a complement to single-cell sequencing to locate specific cell types.

At the AGBT meeting last night, Johns Hopkins researcher Joshua Cohen said that the partners are looking to recruit 50,000 healthy individuals for the study.

Startup Samplix is developing a droplet-based technique while others are turning to CRISPR/Cas9 as a way to enrich long regions of interest for sequencing.

The Fix-C method is a modified version of Hi-C and makes use of the fact that the structural information relevant in cancer is preserved in FFPE samples.

At AGBT, researchers reported on progress made in generating megabase-long reads on the MinIon, as well as initial work doing direct RNA sequencing. 

Pages

The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.

In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.

MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.

In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.